Position
VAN ECK ASSOCIATES CORP in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $49$0.77 → $0.77
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 64.9K | $50.1K | — | — | — | 0.0% |
| Q1 2026 | 62.6K | $48.4K | $0.77 | $49 | −$1.78K | 0.0% |